Schmitt Annika, Sarrazin Christoph
Dtsch Med Wochenschr. 2024 Aug;149(16):955-961. doi: 10.1055/a-2057-1797. Epub 2024 Aug 2.
Chronic infection with hepatitis C virus (HCV) is a common cause of complications such as liver cirrhosis and hepatocellular carcinoma (HCC). It is one of the most significant infectious diseases worldwide, posing a substantial health burden. Since the introduction of direct-acting antiviral agents (DAAs), the treatment landscape has undergone a revolution. HCV infection is curable, and the treatment is safe and well tolerated. Due to the availability of this effective therapeutic option, the World Health Organization (WHO) set an ambitious goal in 2015 to eliminate Hepatitis C by 2030, a goal that the German government also embraced in 2016. The key tasks involve identifying previously undiagnosed cases and ensuring they receive antiviral treatment. Addressing at-risk populations through specific measures, including micro-elimination projects and population-wide campaigns, is essential to achieving the WHO's target both in Germany and globally.
丙型肝炎病毒（HCV）慢性感染是肝硬化和肝细胞癌（HCC）等并发症的常见病因。它是全球最重要的传染病之一，造成了沉重的健康负担。自直接抗病毒药物（DAAs）问世以来，治疗格局发生了变革。HCV感染已可治愈，且治疗安全、耐受性良好。由于有了这种有效的治疗选择，世界卫生组织（WHO）在2015年设定了到2030年消除丙型肝炎的宏伟目标，德国政府也于2016年接受了这一目标。关键任务包括识别先前未诊断的病例并确保他们接受抗病毒治疗。通过包括微观消除项目和全人群宣传活动在内的具体措施来应对高危人群，对于在德国乃至全球实现WHO的目标至关重要。
